Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: elias on December 07, 2016, 06:20:55 pm
-
This is a fairly detailed and up to date online symposium on salvage therapy after DAA failures:
CME Internet Symposium:
Based on:AASLD 2016 Expert Review
http://hosted.medipix.com/aasld2016/ (http://hosted.medipix.com/aasld2016/)
Ribavirin, as part of re-treatment regimen in the past, will rarely be needed with these newer approaches. Unfortunately, some of the key drugs needed for several of those options are not yet approved.
I read here that Gilead's triple DAA protocol Sof/Vel/Vox is likely to be approved in a few months. They have announced application for FDA approval today. It's probably good that other options are in pipeline as well. In terms of cost.
Any thought on this?
PS: There are many more topics covered in this symposium than retreatment. That just happened to be the topic I was most focused on. The panel are well-known experts in the field. So worth sitting through it all
-
Thanks Elias this is great information.
Are you done with your journey? I see January 17th as end of treatment for you. I completed in 2015. My mind is blown by all the options available now.
-
Youre very welcome, sapphire.
I completed my 12 weeks of Epclusa on January 13. I'll probably take EOT+4week viral load just to see how it's going. Then hold on for EOT+12.
===============
Yes , there are options now for ribavirin-free re-treatment awaiting approval. I do wonder about possible insurance hurdles though